RecruitingPhase 2NCT06541847
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Studying Neurofibromatosis type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Healx Limited
- Principal Investigator
- Miriam BornhorstLurie's Children's Hospital
- Intervention
- HLX-1502(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2025 – 2028
Study locations (13)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- New York University Langone Health, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06541847 on ClinicalTrials.govOther trials for Neurofibromatosis type 1
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06507748A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University
- RECRUITINGNANCT07221331Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)AstraZeneca
- RECRUITINGNANCT07088991Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaAstraZeneca
- RECRUITINGPHASE1NCT06961565PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasPasithea Therapeutics Corp.
- RECRUITINGNANCT06880991Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative StudyNational Cancer Institute (NCI)
- RECRUITINGNANCT06222203Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)National Cancer Institute (NCI)
- RECRUITINGNCT06515860Neurofibromatosis Type 1 Tumor Early Detection StudyDavid Miller